DiscGenics’ Japanese clinical trial of DDD cell therapy treats first patients
DiscGenics is engaged in developing regenerative cell-based therapies to relieve pain and reinstate function in patients with degenerative diseases of the spine. DiscGenics, a clinical stage biotechnology company, announced the first patients have been treated in its Japanese safety study, a clinical trial of Injectable Disc Cell Therapy (IDCT) for mild to moderate degenerative disc disease (DDD).
Full Article
Kay
I am so grateful to have found SpineNation. Living with chronic back pain has been physically and emotionally debilitating. Hearing from other “pain warriors” gave me the confidence to move ahead with surgery. This is because SpineNation members share their stories and give advice and suggestions coming from a place of experience. I received suggestions for home equipment as well as post-surgery items to make life a little easier. Thank you for keeping the information flowing and maintaining this essential community.
HikerManiac22
Dealt with back pain the past 10 years. Finally getting back to activities that I love. SpineNation has helped me learn and connect with the right info I need to manage my issues.
Hobbes
Love being part of a community that makes me feel like I am not alone.
Comments
Loading Feed
ChiefBacker
2y
Whichever company can successfully develop this type of technology with long-term results will help tens of millions of people year avoid pain and future surgeries. I'm rooting for every company in this space right now.I hope they all get it right.